Conversion surgery for an initially unresectable, locally advanced pancreatic cancer after induction chemotherapy and carbon-ion radiotherapy: a case report
Abstract Background Pancreatic cancer has a very high mortality rate worldwide, and about 30–40% of all patients have extensive vascular involvement at initial diagnosis that precludes surgical intervention. Here, we describe our experience in a patient with locally advanced pancreatic cancer (LAPC)...
Saved in:
| Main Authors: | Takeshi Fujishiro, Taro Mashiko, Yosihito Masuoka, Misuzu Yamada, Daisuke Furukawa, Naoki Yazawa, Yohei Kawashima, Masami Ogawa, Kenichi Hirabayashi, Toshio Nakagohri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Japan Surgical Society
2018-09-01
|
| Series: | Surgical Case Reports |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40792-018-0522-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01) -
Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
by: Wenjie Liu, et al.
Published: (2025-04-01) -
ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-paclitaxel
by: Susy Shim, et al.
Published: (2025-06-01) -
Pancreatic ductal adenocarcinoma in a patient with pancreas divisum and gastrointestinal duplication cyst: a case report
by: Naoto Takahashi, et al.
Published: (2021-08-01) -
Camrelizumab, an Anti‐PD‐1 Monoclonal Antibody, Plus Carboplatin and Nab‐Paclitaxel as First‐Line Setting for Extensive‐Stage Small‐Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis
by: Jia Yu, et al.
Published: (2025-08-01)